Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Omaha, Nebraska 68131


Purpose:

This medical study is an assessment of clinical response in women with Posttraumatic Stress Disorder (PTSD) due to domestic violence or rape trauma when treated with risperidone. Response to risperidone or placebo (inactive drug) is measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8). Second, the effect of risperidone on depressive and anxiety symptoms will be assessed using the Hamilton Rating Scale for Anxiety, Hamilton Rating Scale for Depression and the Clinical Global Impression.


Study summary:

Risperidone is an atypical antipsychotic that has been shown to be effective in both the core PTSD symptoms and psychotic symptoms associated with combat-induced PTSD in males. Case series have shown that risperidone is possibly effective in monotherapy or adjunctively in treating PTSD patients. However, risperidone has never been tested in women with severe PTSD. Thus, we propose extending and expanding this research to another antipsychotic, risperidone, in a cohort of women who suffer PTSD as a consequence of domestic violence and/or rape trauma.


Criteria:

Inclusion Criteria: - Women with DSM-IV clinical diagnosis of PTSD caused by domestic violence or rape, who are able to attend weekly clinic appointments; - Age 19 -64, not pregnant and either sterile or using acceptable contraception; - A willingness and ability to provide competent signed informed consent; - A level of understanding sufficient to perform all tests and examinations required by the protocol (including fluency of spoken English). Exclusion Criteria: - Any diagnosis of schizophrenia or bipolar I disorder; or active substance dependence. - Unstable general medical condition or serious illness (e.g., death or hospitalization is anticipated within one year), poor liver or kidney function-Subjects with prior non-response to risperidone for the treatment of PTSD with an adequate trial - Enrolment in any drug study within the last 60 days. - Pregnancy or nursing. - Any subject judged clinically to be at serious suicidal risk in the opinion of the investigator.


NCT ID:

NCT00208182


Primary Contact:

Principal Investigator
Frederick Petty, MD, PhD
Creighton University


Backup Contact:

N/A


Location Contact:

Omaha, Nebraska 68131
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.